Moderna Inc MRNA is trading higher Wednesday on continued strength following the company's announcement that it received FDA Fast Track designation for mRNA-1345.
Moderna's mRNA-1345 is a investigational single-dose mRNA vaccine that fights against respiratory syncytial virus in adults over the age of 60.
“We are pursuing an mRNA RSV vaccine to protect the most vulnerable populations – young children and older adults. We are studying mRNA-1345 in these populations in an ongoing clinical trial and we look forward to sharing data when available," said Stéphane Bancel, CEO of Moderna.
The company's mRNA technology was validated by its COVID-19 vaccine, which was authorized in the United States in December 2020.
Price Action: Moderna is making a new all-time high in trading today.
At last check Wednesday, the stock was up 7.55% at $415.70.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
